These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 21384094)
1. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. Fourie CM; Van Rooyen JM; Kruger A; Olsen MH; Eugen-Olsen J; Schutte R; Schutte AE Inflammation; 2012 Feb; 35(1):221-9. PubMed ID: 21384094 [TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145 [TBL] [Abstract][Full Text] [Related]
3. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702 [TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. Botha S; Fourie CM; Schutte R; Eugen-Olsen J; Schutte AE Hypertens Res; 2015 Jun; 38(6):439-44. PubMed ID: 25740290 [TBL] [Abstract][Full Text] [Related]
5. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB J Infect; 2008 Jul; 57(1):55-63. PubMed ID: 18328568 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression. Nebuloni M; Zawada L; Ferri A; Tosoni A; Zerbi P; Resnati M; Poli G; Genovese L; Alfano M PLoS One; 2013; 8(7):e70606. PubMed ID: 23923008 [TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228 [TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. Ostrowski SR; Katzenstein TL; Piironen T; Gerstoft J; Pedersen BK; Ullum H J Acquir Immune Defic Syndr; 2004 Apr; 35(4):337-42. PubMed ID: 15097149 [TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671 [TBL] [Abstract][Full Text] [Related]
10. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150 [TBL] [Abstract][Full Text] [Related]
11. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678 [TBL] [Abstract][Full Text] [Related]
12. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. Langkilde A; Petersen J; Klausen HH; Henriksen JH; Eugen-Olsen J; Andersen O PLoS One; 2012; 7(12):e51698. PubMed ID: 23251607 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. Lawn SD; Myer L; Bangani N; Vogt M; Wood R BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133 [TBL] [Abstract][Full Text] [Related]
14. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients. Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms. Schneider UV; Nielsen RL; Pedersen C; Eugen-Olsen J BMC Infect Dis; 2007 Nov; 7():134. PubMed ID: 18021410 [TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143 [TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
19. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease. Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248 [TBL] [Abstract][Full Text] [Related]
20. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]